Attacks of follow-up ezetimibe-statin products, leading 50% market growth

Follow-up products which entered the market after the patent expiration of ezetimibe, a hyperlipidemia therapy, last April, have quickly started to make performances.

Due the effect of the follow-up products, the ezetimibe-statin complex market grew approximately 50% up last May compared to the last year.

According to the UBIST’s pharmaceutical market research on the 21^st, prescriptions of dr...